US Generic Drugs Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on US Generic Drugs Market 

5.1. COVID-19 Landscape: US Generic Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact:  Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8.  US Generic Drugs Market, By Drug Type

8.1. US Generic Drugs Market Revenue and Volume, by Drug Type, 2024-2033

8.1.1. Simple Generics

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Super Generics

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9.  US Generic Drugs Market, By Brand

9.1. US Generic Drugs Market Revenue and Volume, by Brand, 2024-2033

9.1.1. Pure Generic Drugs

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Branded Generic Drugs

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10.  US Generic Drugs Market, By Route of Administration 

10.1. US Generic Drugs Market Revenue and Volume, by Route of Administration, 2024-2033

10.1.1. Oral

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Injection

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Cutaneous

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

10.1.4. Others

10.1.4.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11.  US Generic Drugs Market, By Therapeutic Application

11.1. US Generic Drugs Market Revenue and Volume, by Therapeutic Application , 2024-2033

11.1.1. Central Nervous System (CNS)

11.1.1.1. Market Revenue and Volume Forecast (2021-2033)

11.1.2. Cardiovascular

11.1.2.1. Market Revenue and Volume Forecast (2021-2033)

11.1.3. Infectious Diseases

11.1.3.1. Market Revenue and Volume Forecast (2021-2033)

11.1.4. Musculoskeletal Diseases

11.1.4.1. Market Revenue and Volume Forecast (2021-2033)

11.1.5. Respiratory

11.1.5.1. Market Revenue and Volume Forecast (2021-2033)

11.1.6. Oncology

11.1.6.1. Market Revenue and Volume Forecast (2021-2033)

11.1.7. Others

11.1.7.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 12.  US Generic Drugs Market, By Distribution Channels

12.1. US Generic Drugs Market Revenue and Volume, by Distribution Channels, 2024-2033

12.1.1. Retail Pharmacy

12.1.1.1. Market Revenue and Volume Forecast (2021-2033)

12.1.2. Hospital Pharmacy

12.1.2.1. Market Revenue and Volume Forecast (2021-2033)

12.1.3. Online and Others

12.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 13.  US Generic Drugs Market, Regional Estimates and Trend Forecast

13.1. U.S.

13.1.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.1.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.1.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.1.4. Market Revenue and Volume Forecast, by Therapeutic Application  (2021-2033)

13.1.5. Market Revenue and Volume Forecast, by Distribution Channels (2021-2033)

Chapter 14. Company Profiles

14.1. Pfizer Inc

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Teva Pharmaceuticals USA, Inc

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Aurobindo Pharma USA, Inc

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Sun pharma Inc

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Abbott Laboratories Inc

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Lupin Pharmaceuticals, Inc

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Mylan

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Dr. Reddy’s

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Novartis

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Eli Lilly company

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms